Now speaking at Global Voices in Renal Oncology (VIRO) 2025 organized by OncoDaily: Dr. Wenxin Xu, Medical Oncologist at the Dana-Farber Cancer Institute, on the topic “Management of Post-Surgical Recurrence”.
Dr. Xu explained that recurrence remains a major challenge for patients with intermediate- and high-risk RCC, with nearly 40% relapsing even after surgery and adjuvant therapy. He highlighted current standards of imaging surveillance with CT and MRI, while noting the emerging role of biomarkers such as CA9 PET tracers, circulating tumor DNA, and blood-based proteins like KIM-1, which may provide earlier and more dynamic detection of recurrence.
He also addressed management strategies once recurrence occurs. Select patients with indolent or oligometastatic disease may be managed with active surveillance or localized interventions, while those with more widespread disease typically require systemic therapy. Dr. Xu concluded that integrating advanced biomarkers with tailored treatment strategies could significantly improve outcomes for patients facing post-surgical recurrence in RCC.
Join us in this conversation.